De Boelelaan 1081, address of BV Cyclotron VU on the campus of VU University Medical Center:
Inside Cyclotron. Inside Cyclotron...:
Inside Cyclotron...

Center for Translational Molecular Medicine (CTMM):
DeCoDe, LeARN, TRACER

Based in the Netherlands, the Center for Translational Molecular Medicine (CTMM) is a partnership between public and private funding. It is dedicated to the development of medical technologies that enable early diagnoses and personalized treatments for the main diseases causing mortality and lowered quality of life: cancer, cardiovascular, neurodegenerative, infectious, and autoimmune diseases.

CTMM strives to significantly reduce the impact of these diseases and to improve the quality of life of those who must live with them. Dedicated to the development of molecular diagnostics and molecular imaging technologies, CTMM firmly focuses on the translational aspects of molecular medicine so that scientific results can be applied to actual patient care as early as possible. Reaching this goal could enable earlier and more precise diagnoses and the design of highly personalized therapies. By bringing academic and industrial researchers and clinicians together, CTMM targets the rapid translation of these new approaches, from bench to bedside, for the direct benefit of patients.

CTMM is jointly funded by the Dutch government (50%), academia (25%), and industry (25%). There are currently 21 active CTMM research projects, with a combined research budget of 275 M€. The projects have a duration of 4–5 years and are due to finish in 2014. These projects focus on a range of issues, including the use of in vitro and in vivo molecular diagnostics and molecular imaging for early detection of diseases, assessment of therapy efficiency and efficacy, stratification of patients for personalized treatment, and imaging-guided therapeutics.

BV Cyclotron VU is one of the 105 partners in the CTMM consortium. The other partners range from universities to academic medical centers in the public sector, and from medical technology and IT companies to chemical and pharmaceutical companies in the private sector. All partners are front runners in technology or (clinical) research in their respective specialty areas.